Biotech

Precipio released an update letter to its shareholders.

Precipio (NASDAQ:PRPO) released an update letter to its shareholders.
As quoted in the press release:

Dear Valued Shareholders,
As we enter the second half of 2017, I am delighted to report that we reached the end of a long process that began almost a year ago, culminating in the recent merger of Precipio with Transgenomic and our relisting on NASDAQ. I was very proud to stand with my team and my shareholders and represent them in ringing the NASDAQ opening bell. With our new listing and recent financings, we believe we are in a strong position to grow our business. We intend to focus on executing our vision to eradicate the misdiagnosis of serious diseases such as cancer, through our unique platform and laboratory focused on delivering specialized diagnostic services to physicians and their patients. We believe physicians and their patients can greatly benefit from access to the expertise and technologies within academic institutions our platform provides.

Click here to read the full press release.

Source: www.accesswire.com

MARKETS

Markets
TSX19028.86+167.50
TSXV623.23+5.97
DOW31097.26+321.83
S&P 5003825.33+39.95
NASD11127.85+99.11
ASX6539.90-28.20

COMMODITIES

Commodities
Gold1808.29-0.12
Silver20.00+0.14
Copper3.59-0.02
Palladium1945.65+0.65
Platinum887.00+1.00
Oil110.57+2.14
Heating Oil3.97+0.03
Natural Gas5.86+0.13

DOWNLOAD FREE REPORTS

×